Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04104243 · ClinicalTrials.gov registry record · NA
Power-Up: An Effectiveness Trial of the Diabetes Prevention Program
A NA study of Type 2 Diabetes and PreDiabetes, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 301
- Enrollment target
- 1
- Study location
NCT04104243: Completed NA study of Type 2 Diabetes and PreDiabetes, sponsored by Albert Einstein College of Medicine.
NCT04104243 is a NA study of Type 2 Diabetes and PreDiabetes that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 301 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04104243, a NA study of Type 2 Diabetes and PreDiabetes, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 301 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to address the risk of diabetes among men by creating a Diabetes Prevention Program (DPP) tailored to men.
Primary Outcome
The percent weight change through 16 sessions was compared. Mean percent weight change for each arm for all intent-to-treat (ITT) participants (i.e.. attended \>=0 sessions), as well as those who were considered "Engaged" (i.e., attended \>=4 sessions) or "Retained" (i.e., attended \>=9 sessions), through 16 scheduled sessions, was determined. All data is crude and unadjusted with no imputation.
Conditions Studied
Interventions
- OTHER Men-Tailored DPP (Power-Up)
Study Locations (1)
New York
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2025-02-07 |
| Phase | NA |
What the finished NCT04104243 record still lists
NCT04104243 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Men-Tailored DPP (Power-Up) is the first listed.
NCT04104243 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04104243 about?
NCT04104243 is a clinical study titled "Power-Up: An Effectiveness Trial of the Diabetes Prevention Program". The goal of this study is to address the risk of diabetes among men by creating a Diabetes Prevention Program (DPP) tailored to men.
What is the current status of trial NCT04104243?
This trial is currently completed. It is a NA study. The enrollment target is 301 participants. The study started on 2021-08-09. Estimated completion is 2025-02-07.
What conditions does trial NCT04104243 study?
This clinical trial studies the following conditions: Type 2 Diabetes, PreDiabetes.
What interventions are being tested in trial NCT04104243?
The interventions under investigation include: Men-Tailored DPP (Power-Up) (OTHER).
Who is sponsoring clinical trial NCT04104243?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04104243 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04104243's enrollment target sits among peer trials
301 66th of 327 higher than 262 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI